A Millimetre Outside the Line: Managing Specification Deviations in UK CBD Wholesale

In UK CBD wholesale, few batch decisions are genuinely binary. A certificate arrives and the potency sits a fraction below the agreed target, a colour reading is marginally darker than the reference sample, or a fill-weight check lands at the edge of tolerance. The supplier calls it close enough. The buyer is left with a commercial decision that must also be an evidence decision.

A specification deviation is not automatically a rejection, but it is never a shrug. The difference between a defensible concession and an accumulated compliance risk lies in how the buyer records the assessment, restricts the acceptance and watches for repetition.

Begin with the approved specification, not the explanation

Before discussing whether a result is tolerable, confirm what the batch was actually required to meet. That means the approved specification version, the test method, the limit, the sampling plan and the laboratory that produced the result. A potency figure is meaningless if the method differs from the one named in the supply agreement, or if the sample was drawn from a composite that does not represent the pallet.

UK buyers should also check laboratory accreditation and measurement uncertainty. A result outside a limit by an amount smaller than the stated uncertainty still requires judgement, but it should be judged against the right baseline. The supplier's sales narrative is not the baseline. The signed specification is.

Separate critical failures from tolerable variances

A practical deviation policy usually needs three classes. Critical failures concern safety, legality or identity: contaminant results above UK legal limits, unacceptable microbiological findings, solvent residues outside specification, a cannabinoid profile that contradicts the label claim, or evidence that the material is not what the contract says it is. These should stop the batch. Price adjustment is not a remedy for a critical failure.

Major deviations affect fitness for the intended market but may be manageable with conditions. A potency shortfall within a defined commercial tolerance, a fill-volume drift that remains lawful, or a minor sensory difference in an unflavoured oil may fall here. Minor deviations are cosmetic or administrative, such as a certificate format issue that can be corrected and reissued.

The classification must be written down at the time, with reasons. A buyer who labels every shortfall as minor is not applying a policy; they are normalising out-of-spec stock.

The concession note is a decision record

A concession note should not be a brief email saying the batch is accepted. It is a controlled record linking the deviation to the batch, the specification clause and the risk assessment. At minimum, it should identify the batch and quantity, the parameter that failed, the result and method, the deviation class, the intended use, any restrictions, the person authorising acceptance and the date.

It should also state what evidence was considered: the certificate of analysis, the supplier's deviation report, retest data, stability information or a revised label proof. Where the buyer relies on a supplier's assurance, that assurance should be attached rather than paraphrased. In an audit, the note must explain why acceptance was reasonable at the time, not merely that someone senior approved it.

Attach conditions and an expiry date

An unconditional concession is a blanket forgiveness that follows the batch into the market. Better practice is to make acceptance conditional and time-bound. Conditions might include re-testing before release, restricted sale to a named customer, amended labelling, a reduced fill quantity, additional retain samples, or a requirement that the supplier investigate the root cause before the next order.

Every concession should also expire. A thirty- or sixty-day review date prevents an out-of-spec batch from becoming permanent stock by inertia. If the condition cannot be met, the concession lapses and the remaining quantity returns to quarantine or rejection. The expiry date should appear in the concession register and in the batch release record, not only in a diary.

Look for the pattern behind the one-offs

One deviation can be an event. Three similar deviations are a process signal. Buyers should track concessions by supplier, product, parameter and production period. If potency misses appear repeatedly at the lower end of tolerance, or fill weights drift across several batches, the issue is no longer a batch-specific concession. It is a capability problem.

That pattern should trigger a supplier corrective-action request, a specification review or a contract conversation. It should also affect the supplier scorecard. A concession register that is never analysed becomes a filing cabinet of forgiven failures.

Know when the answer is no

Refuse the batch when the deviation is critical, when the method or sampling is unreliable, when traceability is incomplete, or when the supplier cannot provide a credible root-cause account. Refuse it also when the proposed remedy depends on blending down a failure without a documented and lawful plan. Blending may have a place in some manufacturing contexts, but it cannot be used to disguise a batch that should not have been released.

The commercial pressure to accept almost-passing stock is real, particularly in a competitive UK wholesale market. The answer is not to pretend the specification is optional. It is to make the exception visible, narrow and temporary. A well-run concession shows that the buyer saw the deviation, assessed the risk and chose a controlled path. An undocumented acceptance shows only that the paperwork was inconvenient.

For CBD Oil Supply readers, the test is simple: if a batch misses specification, can you show why it was accepted, what it was accepted for, and when that acceptance ends? If not, the risk has not been managed. It has merely been moved to the next person in the chain.